Acetadote
(acetylcysteine)ApprovedSmall molecule
Acetadote is one of 1584 small molecule programs targeting Homocystinuria. It is currently in Approved.
111
Indications
38
Total Trials
2
Active Trials
1,583
Competitors
3
FDA Applications
NDA/BLA/ANDA regulatory filings
6
Patents
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 110 indications
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Acetadote
AArbor Pharmaceuticals, Inc.
Approved
Blenoxane
Bristol-Myers SquibbPreclinical
Voltaren
NovartisPreclinical
Duragesic-100
CCephalon
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Duragesic
CCephalon
Preclinical
Tricor
JJagotec
Preclinical
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Nubain
AAultman Health Foundation
Preclinical
Vfend
PPrism Pharmaceuticals
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Nephropathy3 trials
Improved Estimation of GFR by Cystatin C in Preventing Contrast Induced Nephropathy by NAC or Zn
Terminated·RRobert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF)·N/A·NCT00399256·60 enrolled
Mechanical Ventilation2 trials
Evaluation of Aerosolized Drugs Deposition During Mechanical Ventilation
Completed·—·N/A·NCT02818270·30 enrolled
Effectiveness of Routine Nebulization of Mucolytics and Bronchodilators During Mechanical Ventilation
Completed·—·N/A·NCT02159196·950 enrolled
Function2 trials
29 more indications
Common Cold1 trial
Toxicity1 trial
Evaluation of the Effect of Acetazolamide, Mannitol and N-acetylcysteine on Cisplatin-Induced Nephrotoxicity
Completed·—·Phase 2·NCT02760901·52 enrolled
Ischemia1 trial
N-acetylcysteine to Reduce Ischemia/Reperfusion Injury in Liver Resection
Completed·—·Phase 4·NCT01223326·46 enrolled
Outcome1 trial
Outcomes of Patients After Allo-HSCT With Decitabine and NAC
Unknown status·TThe First Affiliated Hospital of Soochow University·Phase 3·NCT04945096·100 enrolled
Mucositis1 trial
Randomized Controlled Trial1 trial
Oxidative Stress1 trial
Poisoning1 trial
Immune Thrombocytopenia1 trial
Sinusitis1 trial
Pseudomyxoma Peritonei1 trial
Ventilation Therapy1 trial
Efficacy of Percussive Ventilation Therapy (MetaNeb ®) Compared With Mucolytic Agents for Atelectasis in the Mechanically Ventilated Pediatric Patient
Completed·—·Phase 4·NCT02168387·39 enrolled
CLE1 trial
Role of Acetylcysteine in Creatinine Clearance
Unknown status·—·N/A·NCT00396396·35 enrolled
Acute Myocardial Infarction1 trial
Dexamethasone1 trial
Amyotrophic Lateral Sclerosis1 trial
Evaluation of the Combined Therapy of EH-301 and N-acetylcysteine Together With Riluzole in Amyotrophic Lateral Sclerosis (ALS)
Recruiting·—·Phase 1/2·NCT07414212·90 enrolled
Ischemic stroke1 trial
Intravenous N-Acetylcysteine for the Treatment of Acute Ischemic Stroke
Completed·LLundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center·Phase 2·NCT04918719·4 enrolled
Wolfram syndrome1 trial
Fallopian Tube Cancer1 trial
Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in Patients With Persistent or Recurrent High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Terminated·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·Phase 2·NCT02569957·1 enrolled
Malignant Brain Tumors1 trial
Glioblastoma1 trial
Unspecified1 trial
Regulatory
FDA Approval Timeline[4]
Jan 1, 1982
MUCOMYST
NDA NDA013601
Jan 23, 2004
ACETADOTE
NDA NDA021539
Jan 29, 2016
CETYLEV
NDA NDA207916
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for acetylcysteine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
- [6]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- AArbor Pharmaceuticals, Inc.